{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Girentuximab",
  "nciThesaurus": {
    "casRegistry": "916138-87-9",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A chimeric monoclonal antibody directed against G250, a cell surface antigen found in the majority of renal cell carcinomas. Following binding, monoclonal antibody G250 (mAb G250) may be internalized by G250 antigen-expressing renal carcinoma cells; mAb G250 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. (NCI05)",
    "fdaUniiCode": "539B57DFJF",
    "identifier": "C1960",
    "preferredName": "Girentuximab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129822",
      "C20401"
    ],
    "synonyms": [
      "Chimeric Monoclonal Antibody cG250",
      "GIRENTUXIMAB",
      "Girentuximab",
      "MoAb G250",
      "Monoclonal Antibody G250",
      "Rencarex",
      "WX-G250",
      "cG250"
    ]
  }
}